바이오마린제약(주)
MX ˙ BMV ˙ US09061G1013
SecurityMX:BMRN / BioMarin Pharmaceutical Inc.
InstitutionRockefeller Capital Management L.P.
Latest Disclosed Ownership372,197 shares
Latest Disclosed Value $ 21,025,409
Rockefeller Capital Management L.P. reports 2.94% increase in ownership of BMRN / BioMarin Pharmaceutical Inc.

On May 14, 2026 - Rockefeller Capital Management L.P. filed a 13F-HR form disclosing ownership of 372,197 shares of BioMarin Pharmaceutical Inc. (MX:BMRN) valued at $21,025,409 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on March 16, 2026 disclosing 361,571 shares of BioMarin Pharmaceutical Inc.. This represents a change in shares of 2.94% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 372,197 10,626 2.94 21,025 -2.15 0.0373
2026-03-16 2025-12-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 361,571 5,043 1.41 21,488 11.28 0.0387
2026-02-14 2025-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 361,571 5,043 21,488 0.0196
2025-11-14 2025-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 356,528 33,045 10.22 19,310 8.59 0.0378
2025-08-14 2025-06-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 323,483 18,081 5.92 17,782 -17.63 0.0390
2025-08-08 2025-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 323,483 18,081 17,782 0.0224
2025-05-14 2025-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 305,402 2,902 0.96 21,589 8.58 0.0533
2025-02-13 2024-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 302,500 35,867 13.45 19,883 6.09 0.0515
2024-11-14 2024-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 266,633 37,805 16.52 18,742 -0.52 0.0504
2024-08-12 2024-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 228,828 20,172 9.67 18,839 3.37 0.0535
2024-05-14 2024-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 208,656 18,200 9.56 18,224 -0.76 0.0532
2024-02-14 2023-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 190,456 10,760 5.99 18,364 15.50 0.0614
2023-11-14 2023-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 179,696 -372,811 -67.48 15,900 -66.80 0.0613
2023-08-14 2023-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 552,507 -176,939 -24.26 47,891 68,315.71 0.1855
2023-05-16 2023-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 729,446 202,410 38.41 71 -99.87 0.3050
2023-03-06 2022-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 527,036 -492,384 -48.30 54,541 -36.88 0.2741
2022-11-02 2022-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 1,019,420 -98,181 -8.78 86,414 -6.69 0.4466
2022-08-12 2022-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 1,117,601 -14,734 -1.30 92,614 6.09 0.4921
2022-05-13 2022-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 1,132,335 -7,502 -0.66 87,301 -13.31 0.4210
2022-02-14 2021-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 1,139,837 -12,022 -1.04 100,703 13.12 0.4699
2021-11-12 2021-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 1,151,859 338,406 41.60 89,025 31.17 0.4678
2021-08-10 2021-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 813,453 53,161 6.99 67,872 18.23 0.3824
2021-05-11 2021-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 760,292 -120,044 -13.64 57,407 -25.63 0.3885
2021-02-12 2020-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 880,336 4,800 0.55 77,195 15.89 0.5847
2020-11-13 2020-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 875,536 335,439 62.11 66,609 -0.01 0.6240
2020-08-12 2020-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 540,097 532,179 6,721.13 66,615 9,857.40 0.6970
2020-05-12 2020-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 7,918 3,956 99.85 669 99.70 0.0088
2020-02-07 2019-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 3,962 74 1.90 335 27.86 0.0042
2019-11-12 2019-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 3,888 3,132 414.29 262 303.08 0.0036
2019-08-09 2019-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 756 -621 -45.10 65 -46.72 0.0009
2019-05-10 2019-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 1,377 1,377 122 0.0017
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.